Reducing the Impact of Opioid Use Disorder on the Acquisition and Management of HIV and on Comorbidities

该项目由DCPFAP研究人员领导，NIMH，NIDA，NINDS和NIAID积极合作。 DC艾滋病进步伙伴关系的目标是减少HIV对华盛顿，华盛顿特区的影响。很明显，物质使用障碍是HIV的主要并发症，并且增加了高风险行为的可能性，所述高风险行为增加了HIV和HCV由于HIV和HCV感染和未感染个体的行为而传播的可能性。 对于第一项研究，在NIH临床中心进行的I期研究，研究人员与FDA会面，以确定在II期研究之前需要进行哪些研究。ANS 6697和咪达唑仑之间的相互作用研究旨在确定ANS 6697是否影响细胞色素p450代谢。12名正常志愿者入组，未检测到相互作用。没有检测到对循环多巴胺代谢的影响，这是没有物质使用障碍和没有渴望刺激的个体的预期结果。 第二阶段研究预计将于2019年第四季度或2020年第一季度在DC PFAP的DC诊所开始。

The project is led by DCPFAP investigators with the active collaboration of NIMH, NIDA, NINDS, and NIAID. The goal of the DC Partnership for AIDS Progress has been to reduce the impact of HIV on Washington, D.C. It is apparent that substance use disorder is a major co-morbidity of HIV both in terms of increasing the likelihood of needle sharing which contributes to transmission of HIV and other blood borne pathogens, and increases the likelihood of high risk behavior that increase the likelihood that HIV and HCV will be transmitted due to behaviors by HIV and HCV infected and uninfected individuals. For the first study, a phase I study carried out at the NIH Clinical Center, investigators met with FDA to determine what studies needed to be done prior to a Phase II study. An interaction study between ANS 6697 and midazolam was indicated to determine whether cytochrome p450 metabolism was affected by ANS 6697. Twelve normal volunteers were enrolled, No interaction was detected. No effect on circulating dopamine metabolism was detected which was the anticipated result in individuals who had no substance use disorder and no stimulus for cravings. A phase II study is anticipated to start in fourth quarter 2019 or first quarter 2020 at the DC Clinics of DC PFAP.